21
Nov
New strength variants of Favipiravir brands ‘PiFLU’ and ‘Favenza’ have been launched by FDC Limited. These drugs are used to treat mild to moderate cases of COVID-19 in India. The 800mg version of the drugs will help reduce the number of tablets to be taken by any patient by 75%. Currently, patients are required to take 18 pills on the first day followed by 8 tablets every day for the next 13 days. Drug Controller General of India (DCGI)-approved Favipiravir is a broad-spectrum anti-viral agent and prevents viral replication. PiFLU and Favenza reduce progression to severe or critical conditions of…
